GT Biopharma (GTBP) vs Tempest Therapeutics (TPST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma (GTBP) has outperformed Tempest Therapeutics (TPST) over the past year, gaining 789.5% versus a loss of 92.9%. Over five years, GTBP leads with a -96.3% price change compared with -99.6% for TPST. Tempest Therapeutics is the larger company by market cap ($12.8 million vs $12.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GTBP | TPST |
|---|---|---|
| Share price | $6.68 | $0.7601 |
| Market cap | $12.05M | $12.84M |
| 1-day change | +12.27% | -1.29% |
| YTD return | +750.96% | -73.52% |
| 1-year return | +789.48% | -92.95% |
| 5-year return | -96.32% | -99.60% |
| EPS (TTM) | $-161.13 | $-3.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.75 | $12.23 |
| 52-week low | $4.91 | $0.743 |
| Distance from 52-week high | -76.77% | -93.78% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1022.75% | +820.93% |
| Average volume | 55.52K | 2.64M |
| Shares outstanding | 1.80M | 16.89M |
| Employees | 1 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed TPST by 882.4 percentage points over the past year.
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
GTBP vs TPST FAQ
Which is bigger, GT Biopharma or Tempest Therapeutics?
Tempest Therapeutics (TPST) is larger, with a market capitalization of $12.84M compared with $12.05M for GT Biopharma (GTBP).
Which stock has performed better over the past year, GTBP or TPST?
GTBP returned +789.48% over the past 12 months, compared with -92.95% for TPST (price return, excluding dividends). Past performance does not predict future results.
Are GT Biopharma and Tempest Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.